About Us

Our lab is dedicated to uncovering the molecular mechanisms that drive resistance to targeted and immune therapies in prostate and other cancers. We are also pioneering innovative therapeutic strategies to overcome these resistances, utilizing a range of state-of-the-art techniques, including 3D-cultured organoids, single-cell sequencing, and spatial transcriptomics. Our recent work has been published in top-tier journals such as Cancer Cell (2020, 2023), Cancer Discovery (2024), Nature Cancer (2022), and Oncogene (2024).

Exciting Research Directions in the Lab:

• Lineage Plasticity and Resistance: Unravel the mechanisms of lineage plasticity-driven resistance and develop novel combination therapies to prevent or overcome this resistance.
• Novel Tumor Suppressors and Oncogenes: Identify and explore new druggable targets among novel tumor suppressors and oncogenes that mediate therapy resistance.
• Tumor Microenvironment and Immune Modulation: Explore how prostate cancer cells alter the tumor microenvironment and immune cells to achieve resistance.
• Mutagenesis and Tumor Evolution: Investigate the molecular mechanisms that promote mutagenesis, tumor heterogeneity, and tumor evolution.
• Epigenetic Rewiring: Examine how epigenetic rewiring promotes therapy resistance and find ways to counteract these changes.
• Drug development: Develop novel therapeutic agents, including small molecular inhibitors and protein degraders, using our established high-throughput platform.